Biener L, Budimovska A, Skowasch D, Pizarro C, Frisch B, Nickenig G
J Asthma Allergy. 2025; 18:245-255.
PMID: 39996013
PMC: 11849428.
DOI: 10.2147/JAA.S483504.
Mihaltan F, Csoma Z, Pauk N, Iras B, Baukiene J, Teodorescu G
J Asthma Allergy. 2025; 18:195-210.
PMID: 39990056
PMC: 11844207.
DOI: 10.2147/JAA.S503048.
Sultana H, De Vos T, Malouf R, Calais F, Marchal C, Eberst G
Cochrane Database Syst Rev. 2025; 2:CD015783.
PMID: 39918122
PMC: 11803715.
DOI: 10.1002/14651858.CD015783.
Pavord I, Chan R, Brown N, Howarth P, Gilson M, Price R
Ann Med. 2024; 56(1):2417184.
PMID: 39465531
PMC: 11520089.
DOI: 10.1080/07853890.2024.2417184.
Benson V, Siddall J, Haq A, Small M, Tang Z, Ye T
J Asthma Allergy. 2024; 17:1041-1054.
PMID: 39464421
PMC: 11512527.
DOI: 10.2147/JAA.S474338.
Blood eosinophil count is associated with early atherosclerotic artery changes in asthma.
Biener L, Frisch B, Skowasch D, Pizarro C, Budimovska A, Nickenig G
BMC Pulm Med. 2024; 24(1):509.
PMID: 39394116
PMC: 11470539.
DOI: 10.1186/s12890-024-03322-0.
CAR-NKT Cells in Asthma: Use of NKT as a Promising Cell for CAR Therapy.
Mohammad Taheri M, Javan F, Poudineh M, Athari S
Clin Rev Allergy Immunol. 2024; 66(3):328-362.
PMID: 38995478
DOI: 10.1007/s12016-024-08998-0.
Unlocking the Long-Term Effectiveness of Benralizumab in Severe Eosinophilic Asthma: A Three-Year Real-Life Study.
Pini L, Bagnasco D, Beghe B, Braido F, Cameli P, Caminati M
J Clin Med. 2024; 13(10).
PMID: 38792553
PMC: 11122375.
DOI: 10.3390/jcm13103013.
Gut microbiome signature and nasal lavage inflammatory markers in young people with asthma.
Sampaio Dotto Fiuza B, de Andrade C, Meirelles P, Santos da Silva J, de Jesus Silva M, Santana C
J Allergy Clin Immunol Glob. 2024; 3(2):100242.
PMID: 38585449
PMC: 10998106.
DOI: 10.1016/j.jacig.2024.100242.
Editorial: A multidisciplinary approach to treatment of severe chronic airway disease (CAD): focus on biomarkers.
Lopez-Rodriguez R, Bobolea I, Melero C, Rial M
Front Allergy. 2024; 5:1357886.
PMID: 38371921
PMC: 10869584.
DOI: 10.3389/falgy.2024.1357886.
Predictors of Early and Late Lung Function Improvement in Severe Eosinophilic Asthma on Type2-Biologics in the PRISM Study.
Pham D, Lee J, Kwon H, Song W, Cho Y, Kim H
Lung. 2024; 202(1):41-51.
PMID: 38252134
DOI: 10.1007/s00408-024-00670-w.
Proteomic signatures of eosinophilic and neutrophilic asthma from serum and sputum.
Asamoah K, Chung K, Kermani N, Bodinier B, Dahlen S, Djukanovic R
EBioMedicine. 2023; 99:104936.
PMID: 38128411
PMC: 10776923.
DOI: 10.1016/j.ebiom.2023.104936.
Characterization and inhibition of inflammasome responses in severe and non-severe asthma.
Horvat J, Kim R, Weaver N, Augood C, Brown A, Donovan C
Respir Res. 2023; 24(1):303.
PMID: 38044426
PMC: 10694870.
DOI: 10.1186/s12931-023-02603-2.
Unanswered questions on the use of biologics in pediatric asthma.
Nieto A, El-Sayed Z, Gomez R, Hossny E, Jiu-Yao W, Kalayci O
World Allergy Organ J. 2023; 16(11):100837.
PMID: 38020283
PMC: 10656246.
DOI: 10.1016/j.waojou.2023.100837.
GEMA 5.3. Spanish Guideline on the Management of Asthma.
Plaza Moral V, Alobid I, Alvarez Rodriguez C, Blanco Aparicio M, Ferreira J, Garcia G
Open Respir Arch. 2023; 5(4):100277.
PMID: 37886027
PMC: 10598226.
DOI: 10.1016/j.opresp.2023.100277.
Using the 6-min walk test to assess the clinical response to mepolizumab and conventional therapy in severe eosinophilic asthma.
Lombardi C, Berti A, Cottini M, Roca E, Ventura L
ERJ Open Res. 2023; 9(5).
PMID: 37868145
PMC: 10588793.
DOI: 10.1183/23120541.00114-2023.
Severe Asthma and Biological Therapies: Now and the Future.
Sardon-Prado O, Diaz-Garcia C, Corcuera-Elosegui P, Korta-Murua J, Valverde-Molina J, Sanchez-Solis M
J Clin Med. 2023; 12(18).
PMID: 37762787
PMC: 10532431.
DOI: 10.3390/jcm12185846.
PRevalence of the Eosinophilic Phenotype Among SeveRE asthma patients in Lebanon: results of the PREPARE study.
Abi Saleh W, Alameh Z, Aoun Bacha Z, Bahous J, Bou Khalil P, Chahine Z
Allergy Asthma Clin Immunol. 2023; 19(1):80.
PMID: 37684679
PMC: 10492315.
DOI: 10.1186/s13223-023-00815-1.
[Consensus document for severe asthma in adults. 2022 update].
Alvarez-Gutierrez F, Blanco-Aparicio M, Casas-Maldonado F, Plaza V, Gonzalez-Barcala F, Carretero-Gracia J
Open Respir Arch. 2023; 4(3):100192.
PMID: 37496585
PMC: 10369632.
DOI: 10.1016/j.opresp.2022.100192.
Omalizumab for the treatment of patients with severe allergic asthma with immunoglobulin E levels above >1500 IU/mL.
Menzella F, Just J, Schwab Sauerbeck I, Mailaender C, Saccheri F, Thonnelier C
World Allergy Organ J. 2023; 16(6):100787.
PMID: 37332525
PMC: 10276275.
DOI: 10.1016/j.waojou.2023.100787.
